Retatrutide vs tirzepatide

Side by side

The mechanism difference (and why it matters)

Tirzepatide activates two incretin receptors, GLP-1 and GIP, which together suppress appetite, slow gastric emptying, and improve insulin response. Retatrutide keeps both and adds a third: the glucagon receptor. Glucagon is best known for raising blood sugar, but at the receptor level it also increases energy expenditure and drives hepatic fat oxidation, the liver burning its own fat stores ^[1]. Retatrutide's concurrent GLP-1/GIP activity offsets glucagon's glucose-raising tendency, so in trials glycemic control was maintained rather than worsened. The net effect is a compound that works on both sides of the energy-balance equation, appetite down and expenditure up, which is the leading explanation for its higher weight-loss ceiling.

The efficacy gap - real, but cross-trial

On the numbers, retatrutide is ahead. Phase 2 showed about 24.2% at 48 weeks on 12 mg ^[1]; the Phase 3 TRIUMPH-1 read showed about 25.0% at 80 weeks on 12 mg, rising toward ~30% in higher-BMI participants continued to 104 weeks ^[2][3]. Tirzepatide's pivotal SURMOUNT-1 produced about 22.5% at 72 weeks on 15 mg ^[4].

The essential caveat: these are different trials, populations, and durations, not a head-to-head. A network meta-analysis points the same direction, but no randomized trial has dosed the two against each other, so the gap is a strong signal rather than a settled fact ^[5]. Anyone claiming a precise "X% better" is over-reading cross-trial data.

What tirzepatide wins on: it exists as a medicine

For a real person deciding today, the biggest difference is not a few percentage points, it is availability and legitimacy. Tirzepatide is FDA-approved, prescribable, dispensed as a quality-controlled finished product, and reachable through insurance pathways for many. Retatrutide is not approved; people using it are relying on compounded or research-use-only supply, with the concentration, purity, and sterility uncertainty that entails (see the US peptide/compounding status). For most people, "the approved drug that works very well" beats "the investigational drug that may work slightly better," until retatrutide is approved.

Side effects and the muscle-loss question

Both carry the incretin-class gastrointestinal profile, nausea, vomiting, diarrhea, constipation, dose-dependent and worst after each step-up, and both are managed the same way, slow titration. Retatrutide's glucagon activity can nudge heart rate up. And on both drugs, a substantial share of unintervened weight loss is lean mass; the mitigation, resistance training and adequate protein, is identical regardless of which compound you run. That crossover, holding muscle while these drugs strip fat, is exactly where our audience overlaps with TRT and peptide use; the GLP-1 guide covers the lean-mass mechanics.

So which one?

If you want the most weight-loss potential on paper and accept investigational status, retatrutide leads the data. If you want a proven, approved, obtainable medicine now, tirzepatide is the answer, and remains an excellent one. For metabolic-dysfunction-associated liver fat specifically, retatrutide's glucagon mechanism is the more interesting story to watch. None of this is a recommendation: which compound, if any, is right is a decision for you and a clinician.

Running either? Track it properly.

OptiPin forecasts your GLP-1 level between shots from real PK curves, logs doses and side effects, and, if you switch compounds, keeps both timelines side by side so you can actually see the transition. On-device, iOS.

Download OptiPin

Frequently asked questions

Is retatrutide better than tirzepatide for weight loss?

In cross-trial data retatrutide has produced larger mean loss (~24% at 48 wk Phase 2; ~25%, up to ~30% in higher-BMI participants, at 12 mg Phase 3) vs ~20-22.5% for tirzepatide at 15 mg. But there is no head-to-head trial, so it's suggestive, not definitive - and tirzepatide is approved while retatrutide is not.

What is the difference between retatrutide and tirzepatide?

Tirzepatide is a dual GLP-1/GIP agonist; retatrutide adds a third target, the glucagon receptor. Glucagon raises energy expenditure and hepatic fat oxidation, which lifts the weight-loss ceiling and helps liver fat. Both are once-weekly Lilly injectables.

Is retatrutide FDA-approved?

No. As of 2026 it is investigational and in Phase 3, with no official label. Tirzepatide is approved (Mounjaro, Zepbound). That approval gap is the biggest practical difference.

Does retatrutide have worse side effects?

Both share the incretin GI profile (nausea, vomiting, diarrhea, constipation), dose-dependent and worst after step-ups. Retatrutide's glucagon activity can raise heart rate. Slow titration keeps most people on either; direct tolerability comparison awaits a head-to-head.

Can you switch from tirzepatide to retatrutide?

People do, but there's no approved protocol. Because the compounds aren't milligram-equivalent, a switch means starting retatrutide low and re-titrating rather than dose-matching. It's a clinical decision, and retatrutide's unapproved status and sourcing risks apply.

Sources & further reading

1. [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (NEJM) (2023)
2. [2]Eli Lilly - Retatrutide Phase 3 TRIUMPH-1 results (2026)
3. [3]AJMC - Retatrutide up to 30.3% weight loss in TRIUMPH-1 (2026)
4. [4]Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1; Jastreboff et al., NEJM) (2022)
5. [5]Comparative efficacy and safety of tirzepatide vs retatrutide: a network meta-analysis (2025)

Weight-loss figures come from separate trials with different populations, doses, and durations; cross-trial comparison is indicative only. Retatrutide is investigational. Nothing here is medical advice.

Related

Retatrutide dosing & titration · Switching tirzepatide → retatrutide · Retatrutide side effects · Retatrutide tracker · Mounjaro (tirzepatide) tracker · GLP-1 guide